



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2018





© 2018 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS  
Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

May 2018

N = 7288



Health Authority	Male	Female	All
FRASER	1379	412	1791
INTERIOR	384	96	480
NORTHERN	135	78	213
VANCOUVER COASTAL	3425	459	3884
VANCOUVER ISLAND	734	151	885
	<b>6057</b>	<b>1196</b>	<b>7253</b>
		<b>Unknown/not stated:</b>	<b>35</b>
		<b>Total:</b>	<b>7288</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2013 - May 2018)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2013 - May 2018)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (May 2013 - May 2018)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (May 2013 - May 2018)






1.6 Percent Distribution of Active Participants by CD4 Count  
(May 2013 - May 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(May 2013 - May 2018)






### 1.8 Active and Inactive Participants (May 2013 - May 2018)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2013 - May 2018)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2013 - May 2018)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(May 2013 - May 2018)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2013 - May 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2013 - May 2018)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2013 - May 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2013 - May 2018)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2013 - May 2018)






### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(May 2013 - May 2018)






1.18 Baseline CD4 for Antiretroviral First Starts (May 2013 - May 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(May 2013 - May 2018)**








### 1.20 Cumulative Resistance Testing Results by Resistance Category (May 2013 - May 2018)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2013 - May 2018)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2018  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	4	0	4	4	915	4	<40	4
1988	27	7	0	7	7	480	7	<40	3
1989	25	54	2	56	48	500	54	<40	3
1990	24	61	1	62	58	510	60	<40	3
1991	24	38	3	41	32	510	41	<40	3
1992	24	67	6	73	59	570	71	<40	3
1993	23	142	15	157	144	580	155	<40	3
1994	22	86	11	97	80	583	93	<40	3
1995	21	131	21	152	127	580	145	<40	3
1996	19	356	57	413	349	600	395	<40	3
1997	17	295	36	331	297	620	317	<40	3
1998	17	205	47	252	215	560	235	<40	3
1999	16	168	41	209	180	560	199	<40	3
2000	17	126	37	163	143	570	156	<40	3
2001	16	127	34	161	131	570	152	<40	3
2002	15	133	28	161	136	560	155	<40	3
2003	15	161	30	191	165	590	184	<40	3
2004	14	173	41	214	181	600	203	<40	3
2005	13	189	46	235	205	610	228	<40	3
2006	12	195	45	240	196	555	222	<40	3
2007	11	264	52	316	266	600	291	<40	3
2008	10	300	69	369	318	630	350	<40	3
2009	9	332	71	403	338	645	378	<40	3
2010	8	283	74	357	305	620	336	<40	3
2011	7	337	72	409	353	670	379	<40	3
2012	6	290	63	353	309	670	337	<40	3
2013	5	279	69	348	298	660	330	<40	3
2014	4	298	54	352	291	720	330	<40	3
2015	3	297	52	349	299	670	329	<40	3
2016	2	294	63	357	318	659	339	<40	3
2017	1	254	41	295	264	620	285	<40	3
2018	0	112	20	132	123	560	128	<40	3
<b>Total:</b>		<b>6058</b>	<b>1201</b>	<b>7259</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2325	<40	2077	590
FEB-2017	7134	754	1914	<40	1739	590
MAR-2017	7186	744	2203	<40	2018	600
APR-2017	7178	746	1966	<40	1770	590
MAY-2017	7224	744	2276	<40	2057	590
JUN-2017	7245	752	2120	<40	1953	596
JUL-2017	7241	753	1965	<40	1788	580
AUG-2017	7266	757	2106	<40	1884	590
SEP-2017	7222	762	2041	<40	1837	610
OCT-2017	7244	770	2187	<40	1938	610
NOV-2017	7241	766	2074	<40	1873	610
DEC-2017	7227	775	1740	<40	1536	610
JAN-2018	7292	756	2384	<40	2102	610
FEB-2018	7256	765	1904	<40	1737	610
MAR-2018	7281	774	2050	<40	1819	618
APR-2018	7266	781	2082	<40	1820	620
MAY-2018	7288	781	2149	<40	1894	600

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1403	3151	88	140	80	417
FEB-2017	1456	2851	80	1874	70	400
MAR-2017	1409	3132	99	635	89	380
APR-2017	1424	3090	94	545	85	420
MAY-2017	1396	3277	85	180	75	420
JUN-2017	1386	3361	76	197	68	485
JUL-2017	1407	3248	68	376	61	520
AUG-2017	1400	3313	78	160	68	495
SEP-2017	1457	3056	74	323	66	415
OCT-2017	1431	3208	91	218	80	470
NOV-2017	1450	3126	79	144	68	360
DEC-2017	1481	3037	60	53	50	382
JAN-2018	1434	3277	78	872	70	365
FEB-2018	1479	3096	81	264	67	450
MAR-2018	1463	3167	75	59	68	495
APR-2018	1482	3125	72	634	60	500
MAY-2018	1465	3207	91	<40	81	460

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1403	21	21	141	142	-6	12876
FEB-2017	7102	1456	10	24	136	182	-38	12910
MAR-2017	7147	1409	17	19	189	139	45	12936
APR-2017	7139	1424	12	20	143	151	-8	12968
MAY-2017	7194	1396	7	22	170	126	55	13002
JUN-2017	7210	1386	10	24	151	138	16	13032
JUL-2017	7202	1407	7	14	134	143	-8	13051
AUG-2017	7229	1400	10	25	156	137	27	13081
SEP-2017	7185	1457	12	16	137	180	-44	13110
OCT-2017	7212	1431	7	6	184	151	27	13123
NOV-2017	7206	1450	16	19	142	148	-6	13158
DEC-2017	7197	1481	5	18	157	175	-9	13189
JAN-2018	7252	1434	13	12	192	128	55	13218
FEB-2018	7220	1479	11	27	123	168	-32	13255
MAR-2018	7241	1463	17	22	153	133	21	13283
APR-2018	7231	1482	13	14	152	159	-10	13304
MAY-2018	7259	1465	9	12	171	144	28	13329

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	<b>7182</b>	0.85%	92.11%	6.17%	0.88%	<b>100.00%</b>
FEB-2017	60	6579	440	55	<b>7134</b>	0.84%	92.22%	6.17%	0.77%	<b>100.00%</b>
MAR-2017	60	6629	439	58	<b>7186</b>	0.83%	92.25%	6.11%	0.81%	<b>100.00%</b>
APR-2017	58	6633	428	59	<b>7178</b>	0.81%	92.41%	5.96%	0.82%	<b>100.00%</b>
MAY-2017	62	6665	438	59	<b>7224</b>	0.86%	92.26%	6.06%	0.82%	<b>100.00%</b>
JUN-2017	57	6691	438	59	<b>7245</b>	0.79%	92.35%	6.05%	0.81%	<b>100.00%</b>
JUL-2017	61	6685	433	62	<b>7241</b>	0.84%	92.32%	5.98%	0.86%	<b>100.00%</b>
AUG-2017	61	6696	448	61	<b>7266</b>	0.84%	92.16%	6.17%	0.84%	<b>100.00%</b>
SEP-2017	57	6677	431	57	<b>7222</b>	0.79%	92.45%	5.97%	0.79%	<b>100.00%</b>
OCT-2017	58	6691	438	57	<b>7244</b>	0.80%	92.37%	6.05%	0.79%	<b>100.00%</b>
NOV-2017	59	6681	445	56	<b>7241</b>	0.81%	92.27%	6.15%	0.77%	<b>100.00%</b>
DEC-2017	58	6666	447	56	<b>7227</b>	0.80%	92.24%	6.19%	0.77%	<b>100.00%</b>
JAN-2018	58	6728	451	55	<b>7292</b>	0.80%	92.27%	6.18%	0.75%	<b>100.00%</b>
FEB-2018	61	6685	451	59	<b>7256</b>	0.84%	92.13%	6.22%	0.81%	<b>100.00%</b>
MAR-2018	62	6710	453	56	<b>7281</b>	0.85%	92.16%	6.22%	0.77%	<b>100.00%</b>
APR-2018	58	6701	449	58	<b>7266</b>	0.80%	92.22%	6.18%	0.80%	<b>100.00%</b>
MAY-2018	62	6712	456	58	<b>7288</b>	0.85%	92.10%	6.26%	0.80%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3241 46%	5 38%	2983 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3715 53%
NOV-2017	9 26%	3281 47%	8 23%	3025 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3661 52%
DEC-2017	10 32%	3286 47%	10 32%	3032 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3612 52%
JAN-2018	10 36%	3319 47%	9 32%	3075 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3635 51%
FEB-2018	13 35%	3320 47%	12 32%	3078 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3587 51%
MAR-2018	10 36%	3341 47%	10 36%	3105 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	18 64%	3569 50%
APR-2018	5 24%	3348 47%	5 24%	3116 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 10%	333 5%	14 67%	3541 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3518 50%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3731	53%
NOV-2017	26	74%	3693	53%
DEC-2017	21	68%	3665	52%
JAN-2018	18	64%	3711	52%
FEB-2018	24	65%	3681	52%
MAR-2018	18	64%	3675	52%
APR-2018	16	76%	3663	52%
MAY-2018	14	61%	3664	52%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1364 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1324 45%	10 83%	1392 48%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1259 44%	15 100%	1422 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1248 43%	10 91%	1439 50%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1224 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1212 43%	5 100%	1443 51%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	746 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1757 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1791 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	10 71%	1833 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	8 89%	1879 59%	1 11%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	14 67%	1939 60%	5 24%	611 19%	0 0%	49 2%	2 10%	701 22%	0 0%	0 0%
DEC-2017	11 69%	1958 60%	5 31%	603 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	9 47%	2006 60%	8 42%	631 19%	0 0%	46 1%	2 11%	688 21%	0 0%	0 0%
FEB-2018	16 70%	2027 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%	0 0%	0 0%
MAR-2018	14 93%	2061 61%	1 7%	646 19%	0 0%	43 1%	0 0%	674 20%	0 0%	0 0%
APR-2018	8 73%	2106 61%	3 27%	654 19%	0 0%	44 1%	0 0%	681 20%	0 0%	0 0%
MAY-2018	13 65%	2140 61%	4 20%	666 19%	1 5%	42 1%	3 15%	675 19%	0 0%	0 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2050	28.30	1674	23.11	2476	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2004	27.68	1668	23.04	2519	34.79	119	1.64	56	0.77	875	12.08
DEC-2017	1998	27.65	1660	22.97	2531	35.02	115	1.59	56	0.77	867	12.00
JAN-2018	2009	27.55	1645	22.56	2595	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2615	36.04	116	1.60	59	0.81	868	11.96
MAR-2018	1981	27.21	1616	22.19	2647	36.35	113	1.55	56	0.77	868	11.92
APR-2018	1939	26.69	1596	21.97	2698	37.13	114	1.57	58	0.80	861	11.85
MAY-2018	1932	26.51	1575	21.61	2738	37.57	114	1.56	58	0.80	871	11.95

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	1	2	450
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	22	4	1	5	4	7	350
APR-2018	14	0	0	4	3	4	400
MAY-2018	12	1	0	4	3	2	370

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11554	3374
FEB-2017	11579	3382
MAR-2017	11630	3431
APR-2017	11656	3446
MAY-2017	11697	3471
JUN-2017	11725	3486
JUL-2017	11757	3516
AUG-2017	11793	3543
SEP-2017	11820	3568
OCT-2017	11877	3622
NOV-2017	11889	3621
DEC-2017	11916	3627
JAN-2018	11974	3669
FEB-2018	12003	3683
MAR-2018	12031	3712
APR-2018	12061	3742
MAY-2018	12097	3767

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month









3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
May 2018

N = 7288

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







### 3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2018

#### INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



#### KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>37</b>	<b>50</b>	<b>25</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>70</b>	<b>93</b>	<b>49</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>352</b>	<b>472</b>	<b>265</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	16
	35-49	*	*	41
	50+	*	*	84
<b>Total HSDA:</b>	<b>180</b>	<b>240</b>	<b>141</b>	
<b>Total HA:</b>		<b>639</b>	<b>855</b>	<b>480</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>639</b>	<b>855</b>	<b>480</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	502	680	384
Female	137	175	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	480	54	595	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	6	5
	<5 years	13	9
	<b>Total HSDA:</b>	<b>37</b>	<b>25</b>
KOOTENAY BOUNDARY	10 years or more	40	27
	5 years or more	18	14
	<5 years	12	8
	<b>Total HSDA:</b>	<b>70</b>	<b>49</b>
OKANAGAN	10 years or more	206	147
	5 years or more	70	57
	<5 years	76	61
	<b>Total HSDA:</b>	<b>352</b>	<b>265</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	98	69
	5 years or more	37	34
	<5 years	45	38
	<b>Total HSDA:</b>	<b>180</b>	<b>141</b>
<b>Total HA:</b>		<b>639</b>	<b>480</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	362	254
	5 years or more	131	110
	<5 years	146	116
<b>Total HA:</b>		<b>639</b>	<b>480</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	38	55	12	21
KOOTENAY BOUNDARY	66	118	22	41
OKANAGAN	207	770	65	267
THOMPSON/CARIBOO/SHUSWAP	125	468	37	127
<b>Total:</b>	<b>436</b>	<b>1411</b>	<b>136</b>	<b>456</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>86</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	29	30	19
	35-49	104	115	70
	50+	206	277	162
	<b>Total HSDA:</b>	<b>345</b>	<b>428</b>	<b>256</b>
FRASER NORTH	0-19	11	11	*
	20-34	108	109	*
	35-49	349	385	*
	50+	519	822	*
	<b>Total HSDA:</b>	<b>987</b>	<b>1327</b>	<b>761</b>
FRASER SOUTH	0-19	7	7	5
	20-34	102	104	75
	35-49	355	407	294
	50+	480	714	400
	<b>Total HSDA:</b>	<b>944</b>	<b>1232</b>	<b>774</b>
<b>Total HA:</b>		<b>2276</b>	<b>2987</b>	<b>1791</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	24	24	12
	20-34	239	243	176
	35-49	808	907	623
	50+	1205	1813	980
<b>Total HA:</b>		<b>2276</b>	<b>2987</b>	<b>1791</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1733	2301	1379
Female	543	686	412

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1791	51	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	183	134
	5 years or more	92	69
	<5 years	70	53
	<b>Total HSDA:</b>	<b>345</b>	<b>256</b>
FRASER NORTH	10 years or more	502	363
	5 years or more	252	197
	<5 years	233	201
	<b>Total HSDA:</b>	<b>987</b>	<b>761</b>
FRASER SOUTH	10 years or more	478	382
	5 years or more	238	191
	<5 years	228	201
	<b>Total HSDA:</b>	<b>944</b>	<b>774</b>
<b>Total HA:</b>		<b>2276</b>	<b>1791</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1163	879
	5 years or more	582	457
	<5 years	531	455
<b>Total HA:</b>		<b>2276</b>	<b>1791</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	134	477	39	83
FRASER NORTH	243	1505	56	236
FRASER SOUTH	209	1279	42	355
<b>Total:</b>	<b>586</b>	<b>3261</b>	<b>137</b>	<b>674</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	194
FRASER NORTH	657
FRASER SOUTH	532
<b>Total:</b>	<b>1383</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	67
	50+	*	*	191
	<b>Total HSDA:</b>		<b>326</b>	<b>470</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>162</b>	<b>210</b>
VANCOUVER	0-19	37	40	5
	20-34	444	455	335
	35-49	1467	1664	1084
	50+	2676	4521	2055
	<b>Total HSDA:</b>	<b>4624</b>	<b>6680</b>	<b>3479</b>
<b>Total HA:</b>		<b>5112</b>	<b>7360</b>	<b>3884</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	41	44	6
	20-34	493	505	371
	35-49	1593	1805	1184
	50+	2985	5006	2323
<b>Total HA:</b>		<b>5112</b>	<b>7360</b>	<b>3884</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4492	6460	3425
Female	618	898	459

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3884	52	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	170	140
	5 years or more	76	64
	<5 years	80	74
	<b>Total HSDA:</b>	<b>326</b>	<b>278</b>
RICHMOND	10 years or more	84	63
	5 years or more	42	32
	<5 years	36	32
	<b>Total HSDA:</b>	<b>162</b>	<b>127</b>
VANCOUVER	10 years or more	2546	1835
	5 years or more	1200	910
	<5 years	878	734
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4624</b>	<b>3479</b>
<b>Total HA:</b>	<b>5112</b>	<b>3884</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2800	2038
	5 years or more	1318	1006
	<5 years	994	840
	Never on ART	0	0
<b>Total HA:</b>		<b>5112</b>	<b>3884</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	161	467	55	172
RICHMOND	43	277	15	92
VANCOUVER	576	10504	216	5327
<b>Total:</b>	<b>780</b>	<b>11248</b>	<b>286</b>	<b>5591</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>168</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>312</b>	<b>434</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>118</b>	<b>157</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>704</b>	<b>989</b>
<b>Total HA:</b>		<b>1134</b>	<b>1580</b>	<b>885</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	8	8	*
	20-34	100	106	*
	35-49	309	357	*
	50+	717	1109	*
<b>Total HA:</b>		<b>1134</b>	<b>1580</b>	<b>885</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	929	1296	734
Female	205	284	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	885	54	520	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	154	127
	5 years or more	74	61
	<5 years	84	67
	<b>Total HSDA:</b>	<b>312</b>	<b>255</b>
NORTH VANCOUVER ISLAND	10 years or more	64	54
	5 years or more	28	20
	<5 years	26	18
	<b>Total HSDA:</b>	<b>118</b>	<b>92</b>
SOUTH VANCOUVER ISLAND	10 years or more	384	275
	5 years or more	159	130
	<5 years	161	133
	<b>Total HSDA:</b>	<b>704</b>	<b>538</b>
<b>Total HA:</b>		<b>1134</b>	<b>885</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	602	456
	5 years or more	261	211
	<5 years	271	218
<b>Total HA:</b>		<b>1134</b>	<b>885</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	187	824	78	198
NORTH VANCOUVER ISLAND	124	253	40	71
SOUTH VANCOUVER ISLAND	204	1696	46	551
<b>Total:</b>	<b>515</b>	<b>2773</b>	<b>164</b>	<b>820</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	49
NORTH VANCOUVER ISLAND	33
SOUTH VANCOUVER ISLAND	103
<b>Total:</b>	<b>185</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>41</b>	<b>49</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	12
	50+	*	*	29
	<b>Total HSDA:</b>		<b>70</b>	<b>106</b>
NORTHERN INTERIOR	0-19	6	6	*
	20-34	20	24	*
	35-49	74	91	*
	50+	86	138	*
	<b>Total HSDA:</b>		<b>186</b>	<b>259</b>
<b>Total HA:</b>		<b>297</b>	<b>414</b>	<b>213</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	34	39	*
	35-49	110	145	*
	50+	144	221	*
<b>Total HA:</b>		<b>297</b>	<b>414</b>	<b>213</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	183	259	135
Female	114	155	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	213	50	520	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	19	11
	5 years or more	13	8
	<5 years	9	6
	<b>Total HSDA:</b>	<b>41</b>	<b>25</b>
NORTH WEST	10 years or more	23	11
	5 years or more	31	26
	<5 years	16	12
	<b>Total HSDA:</b>	<b>70</b>	<b>49</b>
NORTHERN INTERIOR	10 years or more	66	44
	5 years or more	66	54
	<5 years	54	41
	<b>Total HSDA:</b>	<b>186</b>	<b>139</b>
<b>Total HA:</b>		<b>297</b>	<b>213</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	108	66
	5 years or more	110	88
	<5 years	79	59
<b>Total HA:</b>		<b>297</b>	<b>213</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	9	11
NORTH WEST	69	153	18	29
NORTHERN INTERIOR	103	433	17	187
<b>Total:</b>	<b>209</b>	<b>647</b>	<b>44</b>	<b>227</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	25
<b>Total:</b>	<b>51</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	5	8	*
	OKANAGAN	19	34	*
	THOMPSON/CARIBOO/SHUSWAP	23	40	*
	<b>Total HA:</b>	<b>53</b>	<b>92</b>	<b>38</b>
FRASER	FRASER EAST	37	46	26
	FRASER NORTH	51	85	42
	FRASER SOUTH	68	99	54
	<b>Total HA:</b>	<b>156</b>	<b>230</b>	<b>122</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	22
	RICHMOND	11	16	9
	VANCOUVER	503	838	417
	<b>Total HA:</b>	<b>540</b>	<b>903</b>	<b>448</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	78	42
	NORTH VANCOUVER ISLAND	17	26	12
	SOUTH VANCOUVER ISLAND	34	74	26
	<b>Total HA:</b>	<b>102</b>	<b>178</b>	<b>80</b>
NORTHERN	NORTH EAST	10	12	9
	NORTH WEST	33	60	26
	NORTHERN INTERIOR	67	101	56
	<b>Total HA:</b>	<b>110</b>	<b>173</b>	<b>91</b>
<b>Total:</b>		<b>961</b>	<b>1576</b>	<b>779</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	596	1008	479
Female	365	568	300

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	779	51	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicstat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.







**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

